Choosing Kinase Inhibitors for Androgen Deprivation Therapy-Resistant Prostate Cancer

Androgen deprivation therapy (ADT) is a systemic therapy for advanced prostate cancer (PCa). Although most patients initially respond to ADT, almost all cancers eventually develop castration resistance. Castration-resistant PCa (CRPC) is associated with a very poor prognosis, and the treatment of wh...

Full description

Saved in:
Bibliographic Details
Published in:Pharmaceutics 2022-02, Vol.14 (3), p.498
Main Authors: Zhong, Shangwei, Peng, Shoujiao, Chen, Zihua, Chen, Zhikang, Luo, Jun-Li
Format: Article
Language:English
Subjects:
androgen deprivation therapy (ADT)
Androgens
Apoptosis
castration-resistant prostate cancer (CRPC)
Cell cycle
Cell growth
Clinical trials
Gene expression
IκB kinase (IKK)
kinase
kinase inhibitors
Kinases
Medical prognosis
Phosphorylation
Prostate cancer
Proteins
Review
TANK-binding kinase 1 (TBK1)
Transcription factors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Androgen deprivation therapy (ADT) is a systemic therapy for advanced prostate cancer (PCa). Although most patients initially respond to ADT, almost all cancers eventually develop castration resistance. Castration-resistant PCa (CRPC) is associated with a very poor prognosis, and the treatment of which is a serious clinical challenge. Accumulating evidence suggests that abnormal expression and activation of various kinases are associated with the emergence and maintenance of CRPC. Many efforts have been made to develop small molecule inhibitors to target the key kinases in CRPC. These inhibitors are designed to suppress the kinase activity or interrupt kinase-mediated signal pathways that are associated with PCa androgen-independent (AI) growth and CRPC development. In this review, we briefly summarize the roles of the kinases that are abnormally expressed and/or activated in CRPC and the recent advances in the development of small molecule inhibitors that target kinases for the treatment of CRPC.
ISSN:1999-4923
1999-4923
DOI:10.3390/pharmaceutics14030498